製品番号: HY-177796

TMLB-C16

カスタマーレビュー

Based on 1 Customer Validation

TMLB-C16 is a potent and orally active B3GAT3 inhibitor with a K_D of 3.962 μM. TMLB-C16 suppresses proliferation and migration, and induces cell cycle arrest and apoptosis in MHCC-97H (IC₅₀ = 6.53 μM) and HCCLM3 cells (IC₅₀ = 6.22 μM). TMLB-C16 inhibits tumor growth in both MHCC-97H and HCCLM3 xenograft tumor mouse models without causing obvious toxicity. TMLB-C16 can be used for hepatocellular carcinoma research.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.27%
CAS 番号: 2923531-50-2
分子式: C₂₃H₂₀ClN₃O₅
分子量:453.88

保管条件:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

TMLB-C16 構造式

CAS 番号: 2923531-50-2

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

CDK アイソフォーム固有の製品をすべて表示 :

Caspase アイソフォーム固有の製品をすべて表示 :

PARP アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
AGS	IC₅₀	5.33 μM Compound: TMLB-C16	Anti-tumor activity against human AGS cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human AGS cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
Calu-3	IC₅₀	41.64 μM Compound: TMLB-C16	Anti-tumor activity against human Calu-3 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human Calu-3 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
H4	IC₅₀	6.65 μM Compound: TMLB-C16	Anti-tumor activity against human H4 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human H4 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
HCC1937	IC₅₀	47.89 μM Compound: TMLB-C16	Anti-tumor activity against human HCC1937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human HCC1937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
HCCLM3	IC₅₀	18.35 μM Compound: TMLB-C16	Antitumor activity against human HCCLM3 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay Antitumor activity against human HCCLM3 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
HCCLM3	IC₅₀	6.22 μM Compound: TMLB-C16	Antitumor activity against human HCCLM3 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antitumor activity against human HCCLM3 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
Hep 3B2	IC₅₀	12.19 μM Compound: TMLB-C16	Antitumor activity against human Hep3B cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay Antitumor activity against human Hep3B cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
HT-29	IC₅₀	4.71 μM Compound: TMLB-C16	Anti-tumor activity against human HT-29 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human HT-29 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
Huh-7	IC₅₀	12.54 μM Compound: TMLB-C16	Antitumor activity against human Huh-7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay Antitumor activity against human Huh-7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
Jurkat	IC₅₀	6.69 μM Compound: TMLB-C16	Anti-tumor activity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
K562	IC₅₀	8.25 μM Compound: TMLB-C16	Anti-tumor activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
MDA-MB-231	IC₅₀	12.32 μM Compound: TMLB-C16	Anti-tumor activity against human MDA-M8-231 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human MDA-M8-231 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
MEG-01	IC₅₀	11.48 μM Compound: TMLB-C16	Anti-tumor activity against human MEG-01 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human MEG-01 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
MHCC97H	IC₅₀	17.02 μM Compound: TMLB-C16	Cytotoxicity against (shRNA)-mediated B3GAT3 KO human MHCC97H cells assessed as cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against (shRNA)-mediated B3GAT3 KO human MHCC97H cells assessed as cell viability measured after 72 hrs by CCK8 assay	[PMID: 38919032]
MHCC97H	IC₅₀	18.87 μM Compound: TMLB-C16	Antitumor activity against human MHCC97H cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay Antitumor activity against human MHCC97H cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
MHCC97H	IC₅₀	6.53 μM Compound: TMLB-C16	Antitumor activity against human MHCC97H cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Antitumor activity against human MHCC97H cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
MHCC97H	IC₅₀	6.92 μM Compound: TMLB-C16	Cytotoxicity against (shRNA)-Ctrl transfected human MHCC97H cells assessed as cell viability measured after 72 hrs by CCK8 assay Cytotoxicity against (shRNA)-Ctrl transfected human MHCC97H cells assessed as cell viability measured after 72 hrs by CCK8 assay	[PMID: 38919032]
MKN-45	IC₅₀	13.87 μM Compound: TMLB-C16	Anti-tumor activity against human MKN-45 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human MKN-45 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
NCI-H1650	IC₅₀	21.56 μM Compound: TMLB-C16	Anti-tumor activity against human NCI-H1650 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human NCI-H1650 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
NCI-H446	IC₅₀	11.58 μM Compound: TMLB-C16	Anti-tumor activity against human NCI-H446 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human NCI-H446 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
PC-3	IC₅₀	13.7 μM Compound: TMLB-C16	Anti-tumor activity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
PLC-PRF-5	IC₅₀	6.52 μM Compound: TMLB-C16	Antitumor activity against human PLC-PRF-5 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay Antitumor activity against human PLC-PRF-5 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
SK-OV-3	IC₅₀	98.74 μM Compound: TMLB-C16	Anti-tumor activity against human SK-OV-3 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human SK-OV-3 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
SNU-387	IC₅₀	11.71 μM Compound: TMLB-C16	Antitumor activity against human SNU-387 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay Antitumor activity against human SNU-387 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
SW-620	IC₅₀	8.66 μM Compound: TMLB-C16	Anti-tumor activity against human SW620 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human SW620 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
THLE-2	IC₅₀	>20 μM Compound: TMLB-C16	Antitumor activity against human THLE-2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay Antitumor activity against human THLE-2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
THP-1	IC₅₀	23.91 μM Compound: TMLB-C16	Anti-tumor activity against human THP-1 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human THP-1 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
U-251	IC₅₀	6.16 μM Compound: TMLB-C16	Anti-tumor activity against human U-251MG cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human U-251MG cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]
U-937	IC₅₀	5.99 μM Compound: TMLB-C16	Anti-tumor activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Anti-tumor activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 38919032]

体外実験

TMLB-C16 (72 h) demonstrates broad antitumor activities in 13 B3GAT3 high expressed cancer cell lines (such as NCI-H460, NCI-H1650, and Calu3 cells) in a B3GAT3-dependent manner, with IC₅₀ values below 20 μM^[1].
TMLB-C16 (0-10 μM, 14 days) prevents colony formation in a dose-dependent manner in MHCC-97H and HCCLM3 cells^[1].
TMLB-C16 (0-10 μM, 24 h) inhibits cell migration and inhibits cell division in MHCC-97H and HCCLM3 cells^[1].
TMLB-C16 (0-10 μM, 48 h) induces G0/G1-phase cell cycle arrest and apoptosis in MHCC-97H and HCCLM3 cells in a dose-dependent manner, accompanied by enhanced p21, p53, and retinoblastoma-associated protein (Rb) levels and decreased CDK6, cyclin E1, and phosphorylated-Rb (p-Rb) levels^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

MHCC-97H and HCCLM3 cells
Concentration:

0, 5, and 10 μM
Incubation Time:

14 days
Result:

Prevented colony formation in a dose-dependent manner.

Cell Migration Assay ^[1]

Cell Line:

MHCC-97H and HCCLM3 cells
Concentration:

0, 5, and 10 μM
Incubation Time:

24 h
Result:

Suppressed the wound healing of MHCC-97H and HCCLM3 cells from about 22.22% to 0.86% and 15.71% to 1.90%, respectively.

Cell Cycle Analysis^[1]

Cell Line:

MHCC-97H and HCCLM3 cells
Concentration:

0, 5, and 10 μM
Incubation Time:

24 h
Result:

Remarkably repressed the percentage of S-phase in MHCC-97H and HCCLM3 cells at the concentration of 10 and 5 μM, respectively, by accumulating cells in the G0/G1-phase.

Western Blot Analysis^[1]

Cell Line:

MHCC-97H and HCCLM3 cells
Concentration:

0, 5, and 10 μM
Incubation Time:

48 h
Result:

Induced expression of the epithelial surface marker E-cadherin as well as loss of the mesenchymal markers such as N-cadherin, vimentin, matrix metalloproteinase-2 (MMP-2), MMP-9, and zinc finger E-box-binding homeobox 1 (ZEB1).
Significantly enhanced expression of p21, p53, and Rb, and decreased CDK6, cyclin E1, and p-Rb in a dose-dependent manner.
Remarkably enhanced the expression levels of active c-PARP and c-caspase-3 in MHCC-97H and HCCLM3 cells.

Apoptosis Analysis^[1]

Cell Line:

MHCC-97H and HCCLM3 cells
Concentration:

0, 5, and 10 μM
Incubation Time:

48 h
Result:

Induced apoptosis at both tested concentrations.
Increased the early and late apoptotic rates in MHCC-97H at 5 μM by 8.09% and 6.21%, respectively.
Increased the early and late apoptotic rates in MHCC-97H at 10 μM by 29.93% and 15.77%, respectively.

体内実験

TMLB-C16 (5, 10 and 20 mg/kg, i.g., daily from day 7 to day 31) inhibits tumor growth in both MHCC-97H and HCCLM3 xenograft tumor mouse models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male BALB/c nude mice (6-8 weeks) subcutaneously injected with MHCC-97H and HCCLM3 cells^[1]
Dosage:

5, 10 and 20 mg/kg
Administration:

i.g., daily from day 7 to day 31
Result:

Exhibited a dose-dependent tumor inhibition effect in MHCC-97H xenograft model with 70% and 73.49% tumor growth inhibition at doses of 10 and 20 mg/kg, respectively.
Exhibited a tumor growth inhibition rate of approximately 59% at the dose of 10 mg/kg in HCCLM3 xenograft model.

化学情報

CAS 番号 2923531-50-2
性状 Solid
分子量 453.88
分子式 C₂₃H₂₀ClN₃O₅
Color White to off-white
SMILES

O=C(C1=CC2=C(NC=C2C(C(NC3C(N(CC3)C4=CC=C(C)C=C4Cl)=O)=O)=O)C=C1)OC
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 31.25 mg/mL (68.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2032 mL

11.0161 mL

22.0323 mL

5 mM

0.4406 mL

2.2032 mL

4.4065 mL

10 mM

0.2203 mL

1.1016 mL

2.2032 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (278 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Yin H, et al. Discovery of Novel 2-Oxoacetamide Derivatives as B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma. J Med Chem. 2024 Jul 11;67(13):10743-10773. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2032 mL	11.0161 mL	22.0323 mL	55.0806 mL
	5 mM	0.4406 mL	2.2032 mL	4.4065 mL	11.0161 mL
	10 mM	0.2203 mL	1.1016 mL	2.2032 mL	5.5081 mL
	15 mM	0.1469 mL	0.7344 mL	1.4688 mL	3.6720 mL
	20 mM	0.1102 mL	0.5508 mL	1.1016 mL	2.7540 mL
	25 mM	0.0881 mL	0.4406 mL	0.8813 mL	2.2032 mL
	30 mM	0.0734 mL	0.3672 mL	0.7344 mL	1.8360 mL
	40 mM	0.0551 mL	0.2754 mL	0.5508 mL	1.3770 mL
	50 mM	0.0441 mL	0.2203 mL	0.4406 mL	1.1016 mL
	60 mM	0.0367 mL	0.1836 mL	0.3672 mL	0.9180 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

TMLB-C16

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Liver Cancer Compound Library

Cancer Stem Cells Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

CDK アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

PARP アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

TMLB-C16

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Liver Cancer Compound Library

Cancer Stem Cells Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

CDK アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

PARP アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

TMLB-C16 関連分類

HY-177796 関連分類